Featured Content
-
One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is Exelixis (NADSAQ: EXEL), developer of the compound cabozantinib.
-
Amarin Corporation (NASDAQ: AMRN) has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication (hypertriglyceridemia patients with >500 mg/dL).
-
Vivus (NASDAQ: VVUS) has been seeing relatively modest growth in QSYMIA (phentermine and topiramate ER) prescriptions since the drug launched in September 2012 under the FDA’s REMS agreement, which restricted the drug’s sales significantly due to the inability for patients to have prescriptions for the drug filled at brick-and-mortar pharmacies.
|
Sector News
-
U.S. stocks traded lower, paring earlier losses, as investors weighed the prospects for central-bank policy and recent volatility in global markets.
-
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 23, 2013.
-
U.S. stocks slipped on Thursday, recovering from session lows as encouraging domestic economic data and a rally in Hewlett-Packard's shares offset concerns about the timing of any reduction in the Federal Reserve's monetary stimulus.
-
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 22, 2013.
-
U.S. stocks fell, erasing an early rally, as investors weighed remarks by Federal Reserve Chairman Ben S. Bernanke and minutes from the central bank’s latest policy meeting about the pace of stimulus efforts. U.S. stocks rallied early in the day after Bernanke said in prepared remarks to Congress that a premature withdrawal of quantitative easing would put the economic recovery at risk.
|
|
|
